Article
The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain.
Breast cancer research and treatment - 1 Jan 1994
Wolf D M, Jordan V C
Abstract excerpt
The nonsteroidal antiestrogen tamoxifen (TAM) is the most commonly used endocrine treatment for all stages of breast cancer in both pre- and postmenopausal women. However, the development of resistance to the drug is common, as most patients treated with TAM eventually experience a recurrence of tumor growth. One of the potential mechanisms of treatment failure is the acquisition by the tumor of the ability to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.